Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J.

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.

2.

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, Chang E, Aksoy BA, Al-Ahmadie H, Yusko E, Vignali M, Benzeno S, Boyd M, Moran M, Iyer G, Robins HS, Mardis ER, Merghoub T, Hammerbacher J, Rosenberg JE, Bajorin DF.

PLoS Med. 2017 May 26;14(5):e1002309. doi: 10.1371/journal.pmed.1002309. eCollection 2017 May.

3.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

4.

Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.

Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, Klein PS, Rustgi A, Diehl JA.

Oncogene. 2006 Oct 12;25(47):6291-303. Epub 2006 May 29.

PMID:
16732330
5.

Cyclin D1 and pancreatic carcinoma: a proliferative agonist and chemotherapeutic antagonist.

Diehl JA, Benzeno S.

Clin Cancer Res. 2005 Aug 15;11(16):5665-7. No abstract available.

6.

A novel WISp39 protein links Hsp90 and p21 stability to the G2/M checkpoint.

Benzeno S, Diehl JA.

Cancer Biol Ther. 2005 Apr;4(4):376-8. Epub 2005 Apr 5.

PMID:
15846062
7.

C-terminal sequences direct cyclin D1-CRM1 binding.

Benzeno S, Diehl JA.

J Biol Chem. 2004 Dec 31;279(53):56061-6. Epub 2004 Oct 28.

8.

Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.

Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D, Friedman SL.

Cancer Res. 2004 Jun 1;64(11):3885-91.

9.

Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer.

Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA, Friedman SL.

Gastroenterology. 2004 Apr;126(4):1090-103.

PMID:
15057748
10.

Functional interaction of human Cdc37 with the androgen receptor but not with the glucocorticoid receptor.

Rao J, Lee P, Benzeno S, Cardozo C, Albertus J, Robins DM, Caplan AJ.

J Biol Chem. 2001 Feb 23;276(8):5814-20. Epub 2000 Nov 20.

11.

Control of estrogen receptor ligand binding by Hsp90.

Fliss AE, Benzeno S, Rao J, Caplan AJ.

J Steroid Biochem Mol Biol. 2000 Apr;72(5):223-30.

PMID:
10822011

Supplemental Content

Loading ...
Support Center